Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Spain / NCT05750849
Recruiting Observational

Impact of Serum Progesterone Levels on the Day of β-hCG Test in Artificial Cycles on the Ongoing Pregnancy Rate.

NCT05750849 · tracked via the Priya Life Science Spain tracker
Sponsor
Instituto Valenciano de Infertilidad, IVI VALENCIA
Phase
Observational
Started
2023-01-25
Last updated
2025-07-20

Condition(s) studied

Infertility, Female

Investigational drug(s) / intervention(s)

BLOOD COLLECTION FOR P4 DETERMINATION

BLOOD COLLECTION FOR P4 DETERMINATION: Serum progesterone levels on the pregnancy test day

Study summary

Prospective cohort multicentric study including infertile patients undergoing a pregnancy test on βhCG day (around ET +11), after an ET in the context of an artificial cycle and receiving LPS with vaginal natural progesterone following the clinical practice in IVI RMA (Spain).

Eligibility

Sex
FEMALE
Min age
18 Years
Max age
50 Years
Healthy volunteers
Accepted
Inclusion Criteria: * The subject must provide written informed consent prior to any study related procedures * Women ≤50 years old * BMI ≤ 35 kg/m2 * Adequate endometrial thickness (\>6.5mm) and pattern (Triple A structure) in the proliferative phase Exclusion Criteria: * Uterine Pathology, adnexal pathology * Systemic diseases

Primary outcome measure(s)

  • LIVE BIRTH — 1 YEAR
    Record of live birth existence
  • ONGOING PREGNANCY — 1 YEAR
    Pregnancy confirmation by the observation of the presence of at least one gestational sac on ultrasound
  • POSITIVE PREGANCY — 1 YEAR
    Measurement of pregnancy test results
  • BIOCHEMICAL MISCARRIAGE — 1 YEAR
    Measurement of existence of miscarriage after a positive pregnancy test
  • CLINICAL MISCARRIAGE — 1 YEAR
    Measurement of existence of Miscarriage after confirmation of at least one gestational sac on ultrasound

Trial sites (1)

FacilityCityRegionStatus
IVI RMA Valencia Valencia Valencia Recruiting

More Instituto Valenciano de Infertilidad, IVI VALENCIA trials in Spain

Usefulness of Corifollitropin α as Alternative to Conventional Daily rFSH Protocols in Oocyte Donors Undergoing Pituitary Suppression With Medroxiprogesterona Acetate (MPA) Recruiting
Functional Development and Clinical Validation of a Diagnostic Tool Based on Artificial Intelligence for the Assessment of Sperm Quality and the Selection of the Optimal In Vitro Fertilisation (IVF) Treatment Starting soon
Study of the ZyMōt Sperm Selection Method and Its Effect on Embryo Ploidy. Recruiting

Other trials for the same condition

Usefulness of Corifollitropin α as Alternative to Conventional Daily rFSH Protocols in Oocyte Donors Undergoing Pituitary Suppression With Medroxiprogesterona Acetate (MPA) Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05750849 on ClinicalTrials.gov ↗ ← All trials in Spain